Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2021 / N 1

Атеросклероз артерий нижних конечностей: вопросы терапевтического ведения
Ю.А. Карпов

References

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet 2013 Oct;382(9901):1329-40.
2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circulation Research 2015 Apr;116(9):1509-26.
3. Colantonio LD, Hubbard D, Monda KL, Mues KE, Huang L, Dai Y, Jackson EA, Brown TM, Rosenson RS, Woodward M, Muntner P, Farkouh ME. Atherosclerotic risk and statin use among patients with peripheral artery disease. Journal of the American College of Cardiology 2020 Jul;76(3):251-64.
4. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 Societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 2016 Aug;37(29):2315-81.
5. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020 Jan;41(2):255-323.
6. Aboyans V, Ricco JB, Bartelink ML, Björck, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I; ESC Scientific Document Group. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal 2018 Mar;39(9):763-821.
7. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020 Jan;41(1):111-88.
8. Antoniou GA, Fisher RK, Georgiadis GS, Antoniou SA, Torella F. Statin therapy in lower limb peripheral arterial disease: systematic review and meta-analysis. Vascular Pharmacology 2014 Nov;63(2):79-87.
9. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL; REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. European Heart Journal 2014 Nov;35(41):2864-72.
10. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England Journal of Medicine 2017 May;376(18):1713-22.
11. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. Journal of the American College of Cardiology 2019 Sep;74(9):1167-76.
12. McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, Greenland P. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Archives of Internal Medicine 2003;163:2157-62.
13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018 Sep;39(33):3021-104.
14. De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Progress in Cardiovascular Diseases 2008 Jan-Feb;50(4):238-63.
15. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. The Cochrane Database of Systematic Reviews 2013 Sep;2013(9):CD005508.
16. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. The American Journal of Cardiology 2001 Jun;87(11):1284-6.
17. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010 Mar;303(9):841-8.
18. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 Oct;337:a1840.
19. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan;324(7329):71-86.
20. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009 May;301(18):1909-19.
21. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996 Nov;348(9038):1329-39.
22. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegard M, Reist C, Patel MR. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. The New England Journal of Medicine 2017;376:32-40.
23. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein J, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal 2020 Jan;41(3):407-77.
24. Ministry of Health of the Russian Federation; Russian Cardiological Society. Clinical recommendations. Stable ischemic heart disease. ICD: I20.0/ I20.1/ I20.8/I20.9/ I25.0/I25.1/ I25.2/ I25.3/ I25.4/ I25.5/ I25.6/ I25.8 I25.9. Year of approval: 2020. Age category: adults. Moscow, 2020. 114 p. Available from: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_IBS.pdf Accessed 2021 Oct 04. (In Russian).
25. Schmit K, Dolor RJ, Jones WS, Vemulapalli S, Hasselblad V, Subherwal S, Heidenfelder B, Patel MR. Comparative effectiveness review of antiplatelet agents in peripheral artery disease. Journal of American Heart Association 2014 Dec;3(6):e001330.
26. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. European Heart Journal 2009 Jan;30(2):192-201.
27. Association of Cardiovascular Surgeons of Russia; Russian Society of Angiologists and Vascular Surgeons; Russian Society of Surgeons; Russian Society of Cardiology; Russian Association of Endocrinologists. National recommendations for diagnosis and treatment of lower extremity artery disease. Moscow, 2019. 89 p. Available from: http://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf Accessed 2021 Oct 04. (In Russian).
28. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995 Sep;274(12):975-80.
29. Lane R, Ellis B, Watson L, Leng GC. Exercise for intermittent claudication. The Cochrane Database of Systematic Reviews 2014 Jul 18;(7):CD000990.
30. Murphy TP, Lane R, Brian Ellis, Watson L, Leng GC. Exercise for intermittent claudication. The Cochrane Database of Systematic Reviews 2014 Jul;(7):CD00099.
31. Fakhry F, Rouwet EV, den Hoed PT, Hunink MGM, Spronk S. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. The British Journal of Surgery 2013 Aug;100(9):1164-71.
32. Mazari FAK, Gulati S, Rahman MNA, Lee HLD, Mehta TA, McCollum P, Chetter IC. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Annals of Vascular Surgery 2010 Jan;24(1):69-79.
33. Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, Smits TM, van Brussel JP, Stultiens GNM, Derom A, den Hoed PT, Ho G, van Dijk LC, Verhofstad N, Orsini M, van Petersen A, Woltman K, Hulst I, van Sambeek MRHM, Rizopoulos D, Rouwet EV, Hunink MGM. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA 2015 Nov;314(18):1936-44.
34. Liu Y, Shakur Y, Yoshitake M, Kambayashi J. Cilostazol (Pletal®): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake cardiovascular drug. Cardiovascular Drug Reviews 2001 Winter;19(4):369-86.
35. Agrawal NK, Maiti R, Dash D, Pandey BL. Cilostazol reduced inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacological Research 2007 Aug;56(2):118-23.
36. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. The American Journal of Cardiology 2002 Dec;90(12):1314-39.
37. Regensteiner JG, Ware JE, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR. Effects of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittend claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. Journal of the American Geriatrics Society 2002 Dec;50(12):1939-46.
38. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. Journal of Vascular Medicine and Biology 1990;2:142-52.
39. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998 Aug;98(7):678-86.
40. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, Forbes WP, Strandness DE Jr. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. The American Journal of Medicine 2000 Nov;109(7):523-30.
41. Cariski AT. Cilostazol: a novel treatment options in intermittent claudication. International Journal of Clinical Practice. Supplement 2001 Apr;119:11-8.
42. Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. The Annals of Pharmacotherapy 2001 Jan;35(1):48-56.
43. Rendell M, Cariski AT, Hittel N, Zhang P. Cilostazol treatment of claudication in diabetic patients. Current Medical Research and Opinion 2002;18(8):479-87.
44. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. The Cochrane Database of Systematic Reviews 2014 Oct;2014(10):CD003748.
45. Schleinitz MD, Olkin I, Heidenreich PA. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. American Heart Journal 2004 Dec;148(6):990-7.
46. Warner CJ, Greaves SW, Larson RJ, Stone DH, Powell RJ, Walsh DB, Goodney PP. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. Journal of Vascular Surgery 2014 Jun;59(6):1607-14.
47. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. Journal of Vascular Surgery 2003 Oct;38(4):710-3.
48. Leeper NJ, Bauer-Mehren A, Iyer SV, Lependu P, Olson C, Shah NH. Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes. PLoS One 2013 May;8(5):e63499.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]